Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Docteur Brigitte CHARLES

RPPS 10001715563
📊 Reconnaissance scientifique : 10/100📝 61 articles publiés📚 HAL (8)🏆 1 DU/DIU

Diplômes

🎓 DES & spécialité ordinale

  • Rhumatologie (SM)

📚 CES (Certificat d'Études Spéciales)

  • CES Rhumatologie

🎯 Capacités

  • Médecine appliquée aux sports (C)

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

🏆 DU / DIU rhumato reconnus

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

10

h articles cités ≥ h fois chacun. Un h de 10 = 10 publications avec 10+ citations.

Citations

489

Publications

61

i10-index

11

Thématiques principales

  • Social Sciences and Governance ×22
  • French Urban and Social Studies ×16
  • Education, sociology, and vocational training ×12
  • Cultural Industries and Urban Development ×9
  • Business Strategy and Innovation ×7

Affiliations FR : Nantes Université

Voir sur OpenAlex ↗

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Articles de presse (3)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

Top publications · les plus citées

  • 1
    Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis

    Therapeutic drug monitoring · 2003

    📚 77 citations🎯 RCR 1.82
  • 2
    A genome-wide association study of serum uric acid in African Americans

    BMC medical genomics · 2011

    📚 75 citations🎯 RCR 2.12Top 25% NIH🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    AbstractBackgroundUric acid is the primary byproduct of purine metabolism. Hyperuricemia is associated with body mass index (BMI), sex, and multiple complex diseases including gout, hypertension (HTN), renal disease, and type 2 diabetes (T2D). Multiple genome-wide association studies (GWAS) in individuals of European ancestry (EA) have reported associations between serum uric acid levels (SUAL) and specific genomic loci. The purposes of this study were: 1) to replicate major signals reported in EA populations; and 2) to use the weak LD pattern in African ancestry population to better localize (fine-map) reported loci and 3) to explore the identification of novel findings cognizant of the moderate sample size.MethodsAfrican American (AA) participants (n= 1,017) from the Howard University Family Study were included in this study. Genotyping was performed using the Affymetrix®Genome-wide Human SNP Array 6.0. Imputation was performed using MACH and the HapMap reference panels for CEU and YRI. A total of 2,400,542 single nucleotide polymorphisms (SNPs) were assessed for association with serum uric acid under the additive genetic model with adjustment for age, sex, BMI, glomerular filtration rate, HTN, T2D, and the top two principal components identified in the assessment of admixture and population stratification.ResultsFour variants in the geneSLC2A9achieved genome-wide significance for association with SUAL (p-values ranging from 8.88 × 10-9to 1.38 × 10-9). Fine-mapping of the SLC2A9 signals identified a 263 kb interval of linkage disequilibrium in the HapMap CEU sample. This interval was reduced to 37 kb in our AA and the HapMap YRI samples.ConclusionsThe most strongly associated locus for SUAL in EA populations was also the most strongly associated locus in this AA sample. This finding provides evidence for the role ofSLC2A9in uric acid metabolism across human populations. Additionally, our findings demonstrate the utility of following-up EA populations GWAS signals in African-ancestry populations with weaker linkage disequilibrium.

  • 3
    Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis

    British journal of clinical pharmacology · 2005

    📚 50 citations🎯 RCR 1.34🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    AimsTo investigate the concentration‐effect relationship and pharmacokinetics of leflunomide in patients with rheumatoid arthritis (RA).MethodsData were collected from 23 RA patients on leflunomide therapy (as sole disease modifying antirheumatic drug (DMARD)) for at least 3 months. Main measures were A77 1726 (active metabolite of leflunomide) plasma concentrations and disease activity measures including pain, duration/intensity of morning stiffness, and SF‐36 survey. A population estimate was sought for apparent clearance (CL/F ) and volume of distribution was fixed (0.155 l kg−1). Factors screened for influence on CL/F were weight, age, gender and estimated creatinine clearance.ResultsSignificantly higher A77 1726 concentrations were seen in patients with less swollen joints and with higher SF‐36 mental summary scores than in those with measures indicating more active disease (P < 0.05); concentration‐effect trends were seen with five other disease activity measures. Statistical analysis of all disease activity measures showed that mean A77 1726 concentrations in groups with greater control of disease activity were significantly higher than those in whom the measures indicated less desirable control (P < 0.05). There was large between subject variability in the dose‐concentration relationship. A steady‐state infusion model best described the pharmacokinetic data. Inclusion of age as a covariate decreased interindividual variability (P < 0.01), but this would not be clinically important in terms of dosage changes. Final parameter estimate (% CV interindividual variability) for CL/F was 0.0184 l h−1 (50%) (95% CI 0.0146, 0.0222). Residual (unexplained) variability (% CV) was 8.5%.ConclusionsThis study of leflunomide in patients using the drug clinically indicated a concentration‐effect relationship. From our data, a plasma A77 1726 concentration of 50 mg l−1 is more likely to indicate someone with less active disease than is a concentration around 30 mg l−1. The marked variability in pharmacokinetics suggests a place for individualized dosing of leflunomide in RA therapy.

Publications scientifiques (7) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal3

▼

csDMARDs2

▼

Génétique1

▼

Qualité de vie / PROMs1

▼

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.